All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @thatsarajane on TikTok · 12s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @thatsarajane's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Release your inhibitions, feel the rain on your skin
  2. 0:04The one else can feel it for you
  3. 0:06Only you can let it in
  4. 0:08No one else, no one else can

@thatsarajane's 'moon face' claim about Mounjaro, fact-checked

Sara-Jane

TikTok creator

25.8K viewsWatch on TikTok

Quick answer

The video documents self-reported facial volume change as a subjective marker of weight gain reversed by tirzepatide (Mounjaro), a dual GIP and GLP-1 receptor agonist approved by the MHRA and FDA for weight management. Facial adipose tissue reduction is a known and expected consequence of clinically significant weight loss on tirzepatide, with phase 3 trial data showing mean body weight reductions of 15 to 22.5 percent at 72 weeks (Jastreboff et al., 2022, NEJM). No specific dose, clinical claim, or therapeutic recommendation is made by the creator.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded TirzepatideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Tirzepatide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 8 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @thatsarajane's 'moon face' claim about Mounjaro, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Tirzepatide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this tirzepatide video claims cluster

Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@thatsarajane's 'moon face' claim about Mounjaro, fact-checked" from Sara-Jane. We read the clip as a GLP-1 social video fact-checks claim about Compounded Tirzepatide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The video documents self-reported facial volume change as a subjective marker of weight gain reversed by tirzepatide (Mounjaro), a dual GIP and GLP-1 receptor agonist approved by the MHRA and FDA for weight management.

The reason this review is not generic is the source wording and the canonical claim label "glp1 sorry new face who dis one of the main things that alerted." In this clip, the useful excerpt is: "Release your inhibitions, feel the rain on your skin The one else can feel it for you Only you can let it in No one else, no one else can" That wording changes the review because it points to Compounded Tirzepatide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Tirzepatide Once Weekly for the Treatment of Obesity (2022), Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (2024), and Tirzepatide for Obesity Treatment and Diabetes Prevention (2025), plus the creator's own wording. Compounded Tirzepatide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Facial adipose tissue is part of overall subcutaneous fat and does reduce with systemic caloric deficit, including that induced by GLP-1 receptor agonists.
People who land here are usually comparing the Compounded Tirzepatide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Tirzepatide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The video documents self-reported facial volume change as a subjective marker of weight gain reversed by tirzepatide (Mounjaro), a dual GIP and GLP-1 receptor agonist approved by the MHRA and FDA for weight management.

FormBlends verdict

Compounded Tirzepatide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The video documents self-reported facial volume change as a subjective marker of weight gain reversed by tirzepatide (Mounjaro), a dual GIP and GLP-1 receptor agonist approved by the MHRA and FDA for weight management. Facial adipose tissue reduction is a known and expected consequence of clinically significant weight loss on tirzepatide, with phase 3 trial data showing mean body weight reductions of 15 to 22.5 percent at 72 weeks (Jastreboff et al., 2022, NEJM). No specific dose, clinical claim, or therapeutic recommendation is made by the creator.
  • Tirzepatide (Mounjaro) produced mean weight loss of 15 to 22.5 percent over 72 weeks in the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM), making visible facial changes at this scale biologically expected.
  • Facial adipose tissue is part of overall subcutaneous fat and does reduce with systemic caloric deficit, including that induced by GLP-1 receptor agonists.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.

Review Compounded Tirzepatide

What You'll Learn

  • Tirzepatide (Mounjaro) produced mean weight loss of 15 to 22.5 percent over 72 weeks in the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM), making visible facial changes at this scale biologically expected.
  • Facial adipose tissue is part of overall subcutaneous fat and does reduce with systemic caloric deficit, including that induced by GLP-1 receptor agonists.
  • The informal term 'GLP-1 face' has no standardised clinical definition. Observed facial changes are an extension of general fat loss, not a unique drug-specific effect.
  • Rapid weight loss exceeding 1 to 1.5 percent of body weight per week increases the risk of muscle loss alongside fat, which can affect facial appearance differently and less predictably than gradual loss.
  • Skin laxity following significant facial fat loss is documented in bariatric literature and may occur with GLP-1-induced losses, particularly in older patients or those with large total weight reductions (Shermak et al., 2006, Plastic and Reconstructive Surgery).
  • Personal transformation videos reflect individual experience. Facial outcomes on Mounjaro vary by baseline weight, age, rate of loss, and protein intake, none of which are captured in a 30-second TikTok.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @thatsarajane actually say?

Honestly? Not much, medically speaking. The transcript is song lyrics, specifically Natasha Bedingfield's "Unwritten," sung over what the caption tells us is a transformation video. The actual claim lives in the caption: @thatsarajane says not recognising her own face, describing it as a "giant moon head," was one of the signals she had gained significant weight before starting Mounjaro. This is a before-and-after framing, not a medical tutorial. She is not prescribing, diagnosing, or advising. She is documenting a personal experience of facial weight changes associated with obesity and subsequent GLP-1 treatment. That context matters when we assess what is actually being communicated here.

The phrase "gone a custard cream too far" is British slang for having gained more weight than she intended. The video presents facial change as a marker of that weight gain, and implicitly, as evidence that Mounjaro has reversed it.

Does the science back this up?

Yes, within limits. Fat redistribution in the face is real, measurable, and documented in people with obesity. And GLP-1 receptor agonists do produce facial fat loss as part of systemic weight reduction. What the science does not support is treating facial changes as a diagnostic tool or a reliable weight loss metric.

Facial adipose tissue responds to caloric deficit and weight loss, including weight loss induced by tirzepatide, the active ingredient in Mounjaro. A 2023 trial published in The New England Journal of Medicine (Jastreboff et al., 2022, NEJM) found tirzepatide produced mean weight reductions of 15 to 22.5 percent at 72 weeks depending on dose. At those levels of loss, facial volume changes are not cosmetically subtle. Plastic surgeons have started calling this "GLP-1 face" in popular media, though that term has no formal clinical definition. The underlying physiology, subcutaneous facial fat loss with potential skin laxity, is well established in bariatric literature independently of the drug class.

So the creator is not wrong. She is just not being precise, which is fine for a personal video.

What did they get wrong (or right)?

She got the experiential truth right. Facial puffiness or fullness is a legitimate and documented feature of higher body weight, and its reduction is a genuine, if informal, marker that weight loss is occurring. Credit where it is due: she is not claiming Mounjaro fixed her health, cured anything, or recommending a dose. That restraint is better than a lot of what circulates in the GLP-1 content space.

What she skips, understandably for a 30-second TikTok, is nuance. Facial fat loss on GLP-1s is not uniformly flattering. Jastreboff and colleagues' data, alongside observational reports from dermatologists, suggests that rapid or significant weight loss can cause facial volume loss that some patients find ageing. A 2020 paper by Rohrich et al. in Plastic and Reconstructive Surgery documented how facial fat compartments deflate unevenly with systemic fat loss, which can create hollowing around the temples and midface. She shows a happy outcome. Not everyone's is.

There is also no mention of the rate of loss, which matters clinically. Fast facial change on a GLP-1 can also reflect muscle loss alongside fat loss if protein intake is inadequate, something the video does not touch.

What should you actually know?

If you are on a GLP-1 like tirzepatide or semaglutide and your face is changing, that is probably weight loss working, not a side effect to panic about. But a few things are worth knowing that this video does not cover.

  • Facial fat loss on GLP-1s is real and documented, but the rate matters. Losing more than 1 to 1.5 percent of body weight per week increases the risk of muscle loss alongside fat, which can affect facial structure differently than pure fat reduction.
  • "GLP-1 face" is a media term, not a clinical diagnosis. Dermatologists and plastic surgeons are observing patterns, but there is no standardised clinical framework yet for managing it.
  • Skin laxity after significant facial fat loss is a documented outcome in bariatric patients (Shermak et al., 2006, Plastic and Reconstructive Surgery). GLP-1-induced losses may produce similar results, particularly in patients over 45 or those with significant total weight loss.
  • If facial changes concern you, a dermatologist or your prescribing clinician is the right person to ask, not TikTok comment sections.

@thatsarajane is sharing her experience, and that has value. But personal transformation videos are not a substitute for monitored clinical care.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Sara-Jane · TikTok creator

25.8K views on this video

Sorry new face who dis? One of the main things that alerted me that I’d gone a custard cream too far was not recognising my giant moon head anymore. #creatorsearchinsights #mounjaroupdate #mounjarocom

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about tirzepatide (mounjaro) produced mean weight loss of 15 to 22.5?

Tirzepatide (Mounjaro) produced mean weight loss of 15 to 22.5 percent over 72 weeks in the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM), making visible facial changes at this scale biologically expected.

What does the video say about facial adipose tissue?

Facial adipose tissue is part of overall subcutaneous fat and does reduce with systemic caloric deficit, including that induced by GLP-1 receptor agonists.

What does the video say about the informal term 'glp-1 face' has no standardised clinical definition.?

The informal term 'GLP-1 face' has no standardised clinical definition. Observed facial changes are an extension of general fat loss, not a unique drug-specific effect.

What does the video say about rapid weight loss exceeding 1 to 1.5 percent of body?

Rapid weight loss exceeding 1 to 1.5 percent of body weight per week increases the risk of muscle loss alongside fat, which can affect facial appearance differently and less predictably than gradual loss.

What does the video say about skin laxity following significant facial fat loss?

Skin laxity following significant facial fat loss is documented in bariatric literature and may occur with GLP-1-induced losses, particularly in older patients or those with large total weight reductions (Shermak et al., 2006, Plastic and Reconstructive Surgery).

What does the video say about personal transformation videos reflect individual experience. facial outcomes on mounjaro?

Personal transformation videos reflect individual experience. Facial outcomes on Mounjaro vary by baseline weight, age, rate of loss, and protein intake, none of which are captured in a 30-second TikTok.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Sara-Jane, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.